prednisone has been researched along with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma in 38 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We encountered severe autonomic neuropathy and cholestasis in a child receiving vincristine, after the introduction of piperacillin-tazobactam." | 3.78 | A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? ( Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012) |
| "Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival." | 2.82 | Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. ( Aricò, M; Attarbaschi, A; Barisone, E; Bartram, CR; Basso, G; Beier, R; Biondi, A; Caruso, R; Cazzaniga, G; Conter, V; Greiner, J; Harbott, J; Kremens, B; Kulozik, AE; Lo Nigro, L; Locatelli, F; Mann, G; Möricke, A; Niggli, F; Parasole, R; Ratei, R; Rössig, C; Schrappe, M; Silvestri, D; Stanulla, M; Valsecchi, MG; von Stackelberg, A; Zimmermann, M, 2016) |
| "Besides, the PLK4 expression in childhood ALL patients was also determined at day 15 after the initiation of induction therapy (D15)." | 1.91 | Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients. ( Xu, J; Zhao, L, 2023) |
| "The BFM studies for relapsed childhood acute lymphoblastic leukemia (ALL) were started in 1983, at a time when cure rates for ALL were still lower and the number of children with ALL relapse equaled about the number of children with newly diagnosed neuroblastoma." | 1.39 | ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia. ( Eckert, C; Henze, G; v Stackelberg, A, 2013) |
| "Risperidone is an effective short-term pharmacologic agent for controlling steroid-related psychiatric adverse effects when cessation or dose reduction of steroid therapy is not an option." | 1.36 | Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone. ( Dahl, G; Shaw, RJ; Tzuang, D; Ularntinon, S, 2010) |
| "We retrospectively estimated the minimal residual disease in the bone marrow (BM) and the testis by detection of clone-specific T-cell receptor rearrangement of leukemic cells." | 1.35 | Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse. ( Arima, K; Hasegawa, D; Hori, T; Hosoya, R; Imamura, T; Kato, I; Kitagawa, Y; Manabe, A; Ogawa, C; Takahashi, H; Takusagawa, A; Tsurusawa, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 26 (68.42) | 24.3611 |
| 2020's | 10 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Kośmider, K | 1 |
| Karska, K | 1 |
| Kozakiewicz, A | 1 |
| Lejman, M | 1 |
| Zawitkowska, J | 1 |
| Xu, J | 1 |
| Zhao, L | 1 |
| Wu, SY | 1 |
| Chu, XR | 1 |
| Ji, Q | 1 |
| Lin, XC | 1 |
| Bai, ZJ | 1 |
| Li, JQ | 1 |
| Pan, J | 1 |
| Chen, ZX | 1 |
| Hu, SY | 1 |
| Rausch, CR | 1 |
| Jabbour, EJ | 1 |
| Kantarjian, HM | 1 |
| Kadia, TM | 1 |
| Montoro, J | 1 |
| Chorão, P | 1 |
| Quintero, A | 1 |
| Roca, J | 1 |
| Guerreiro, M | 1 |
| Balaguer-Roselló, A | 1 |
| Dunsmore, KP | 1 |
| Winter, SS | 1 |
| Devidas, M | 2 |
| Wood, BL | 1 |
| Esiashvili, N | 1 |
| Chen, Z | 1 |
| Eisenberg, N | 1 |
| Briegel, N | 1 |
| Hayashi, RJ | 1 |
| Gastier-Foster, JM | 1 |
| Carroll, AJ | 1 |
| Heerema, NA | 1 |
| Asselin, BL | 1 |
| Rabin, KR | 1 |
| Zweidler-Mckay, PA | 1 |
| Raetz, EA | 1 |
| Loh, ML | 1 |
| Schultz, KR | 1 |
| Winick, NJ | 1 |
| Carroll, WL | 1 |
| Hunger, SP | 1 |
| Dai, Q | 1 |
| Zhang, G | 1 |
| Yang, H | 1 |
| Wang, Y | 1 |
| Ye, L | 1 |
| Peng, L | 1 |
| Shi, R | 1 |
| Guo, S | 1 |
| He, J | 1 |
| Jiang, Y | 1 |
| Yadav, SP | 1 |
| Wadhwa, T | 1 |
| Thakkar, D | 1 |
| Kapoor, R | 1 |
| Rastogi, N | 1 |
| Sarma, S | 1 |
| Morita, K | 1 |
| Jain, N | 1 |
| Kantarjian, H | 1 |
| Takahashi, K | 1 |
| Fang, H | 1 |
| Konopleva, M | 1 |
| El Hussein, S | 1 |
| Wang, F | 1 |
| Short, NJ | 1 |
| Maiti, A | 1 |
| Sasaki, K | 1 |
| Garcia-Manero, G | 1 |
| Konoplev, S | 1 |
| Ravandi, F | 1 |
| Khoury, JD | 1 |
| Jabbour, E | 1 |
| Andrieu, GP | 1 |
| Kohn, M | 1 |
| Simonin, M | 1 |
| Smith, CL | 1 |
| Cieslak, A | 1 |
| Dourthe, MÉ | 1 |
| Charbonnier, G | 1 |
| Graux, C | 1 |
| Huguet, F | 1 |
| Lhéritier, V | 1 |
| Dombret, H | 1 |
| Spicuglia, S | 1 |
| Rousselot, P | 1 |
| Boissel, N | 1 |
| Asnafi, V | 1 |
| Landmann, E | 1 |
| Burkhardt, B | 1 |
| Zimmermann, M | 6 |
| Meyer, U | 1 |
| Woessmann, W | 1 |
| Klapper, W | 1 |
| Wrobel, G | 1 |
| Rosolen, A | 1 |
| Pillon, M | 1 |
| Escherich, G | 1 |
| Attarbaschi, A | 4 |
| Beishuizen, A | 1 |
| Mellgren, K | 1 |
| Wynn, R | 1 |
| Ratei, R | 4 |
| Plesa, A | 1 |
| Schrappe, M | 7 |
| Reiter, A | 1 |
| Bergeron, C | 1 |
| Patte, C | 1 |
| Bertrand, Y | 1 |
| Valliyammai, N | 1 |
| Nancy, NK | 1 |
| Sagar, TG | 1 |
| Rajkumar, T | 1 |
| Paganin, M | 1 |
| Grillo, MF | 1 |
| Silvestri, D | 2 |
| Scapinello, G | 1 |
| Buldini, B | 1 |
| Cazzaniga, G | 2 |
| Biondi, A | 2 |
| Valsecchi, MG | 2 |
| Conter, V | 2 |
| Te Kronnie, G | 1 |
| Basso, G | 2 |
| Fuhrmann, S | 1 |
| Schabath, R | 2 |
| Möricke, A | 4 |
| Kunz, JB | 2 |
| Kulozik, AE | 4 |
| Ludwig, WD | 3 |
| Karawajew, L | 2 |
| Szarzyńska-Zawadzka, B | 1 |
| Sędek, Ł | 1 |
| Kosmalska, M | 1 |
| Zdon, K | 1 |
| Biecek, P | 1 |
| Bandapalli, OR | 2 |
| Kraszewska-Hamilton, M | 1 |
| Jaksik, R | 1 |
| Drobna, M | 1 |
| Kowalczyk, JR | 1 |
| Szczepański, T | 1 |
| Van Vlierberghe, P | 1 |
| Witt, M | 1 |
| Dawidowska, M | 1 |
| Henze, G | 1 |
| v Stackelberg, A | 1 |
| Eckert, C | 1 |
| Hayase, E | 1 |
| Sugita, J | 1 |
| Fujimoto, K | 1 |
| Ebata, K | 1 |
| Yamakawa, T | 1 |
| Yoshida, M | 2 |
| Takemura, R | 1 |
| Iwasaki, J | 1 |
| Takahashi, S | 1 |
| Shiratori, S | 1 |
| Kondo, T | 1 |
| Tanaka, J | 1 |
| Teshima, T | 1 |
| Demlova, R | 1 |
| Mrkvicova, M | 1 |
| Sterba, J | 1 |
| Bernatikova, H | 1 |
| Stary, J | 1 |
| Sukova, M | 1 |
| Mikuskova, A | 1 |
| Chocholova, A | 1 |
| Mladosievicova, B | 1 |
| Soltysova, A | 1 |
| Behulova, D | 1 |
| Pilatova, K | 1 |
| Zdrazilova-Dubska, L | 1 |
| Valik, D | 1 |
| Hastings, C | 1 |
| Gaynon, PS | 1 |
| Nachman, JB | 1 |
| Sather, HN | 1 |
| Lu, X | 1 |
| Seibel, NL | 1 |
| Hong, C | 1 |
| Tang, KS | 1 |
| Villegas, M | 1 |
| Tan, PL | 1 |
| Stanulla, M | 3 |
| Mann, G | 2 |
| Locatelli, F | 1 |
| Niggli, F | 2 |
| Aricò, M | 1 |
| Bartram, CR | 1 |
| Beier, R | 2 |
| Lo Nigro, L | 1 |
| Kremens, B | 1 |
| Greiner, J | 1 |
| Parasole, R | 1 |
| Harbott, J | 1 |
| Caruso, R | 1 |
| von Stackelberg, A | 1 |
| Barisone, E | 1 |
| Rössig, C | 1 |
| Cai, JY | 1 |
| Xue, HL | 1 |
| Chen, J | 1 |
| Shen, SH | 1 |
| Pan, C | 1 |
| Wang, X | 1 |
| Zhou, M | 1 |
| Tang, YJ | 1 |
| Gao, YJ | 1 |
| Wang, JM | 1 |
| Tang, JY | 1 |
| Grimes, A | 1 |
| Mirkheshti, N | 1 |
| Chatterjee, B | 1 |
| Tomlinson, G | 1 |
| Assanasen, C | 1 |
| Nascimbeni, C | 1 |
| Chantepie, S | 1 |
| Brugiere, C | 1 |
| Comoz, F | 1 |
| Salaun, V | 1 |
| Verneuil, L | 1 |
| Deenik, W | 1 |
| Beverloo, HB | 1 |
| van der Poel-van de Luytgaarde, SC | 1 |
| Wattel, MM | 1 |
| van Esser, JW | 1 |
| Valk, PJ | 1 |
| Cornelissen, JJ | 1 |
| Arima, K | 1 |
| Hasegawa, D | 1 |
| Ogawa, C | 1 |
| Kato, I | 1 |
| Imamura, T | 1 |
| Takusagawa, A | 1 |
| Takahashi, H | 2 |
| Kitagawa, Y | 1 |
| Hori, T | 1 |
| Tsurusawa, M | 1 |
| Manabe, A | 2 |
| Hosoya, R | 1 |
| Pisecker, M | 1 |
| Inthal, A | 1 |
| Janousek, D | 1 |
| Dworzak, M | 1 |
| Pötschger, U | 1 |
| Ullmann, R | 1 |
| Gadner, H | 1 |
| Haas, OA | 1 |
| Panzer-Grümayer, R | 1 |
| Strehl, S | 1 |
| Losa Frías, V | 1 |
| Martín-Sacristán Martín, B | 1 |
| Díaz Conejo, R | 1 |
| Ramos Corral, R | 1 |
| Velasco Arribas, MR | 1 |
| Cai, Y | 1 |
| Sun, XF | 1 |
| Yan, SL | 1 |
| Zhen, ZJ | 1 |
| Xia, Y | 1 |
| Ling, JY | 1 |
| Ularntinon, S | 1 |
| Tzuang, D | 1 |
| Dahl, G | 1 |
| Shaw, RJ | 1 |
| Chen, X | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Lei, P | 1 |
| Zhai, Y | 1 |
| Liu, L | 1 |
| Zuurbier, L | 1 |
| Homminga, I | 1 |
| Calvert, V | 1 |
| te Winkel, ML | 1 |
| Buijs-Gladdines, JG | 1 |
| Kooi, C | 1 |
| Smits, WK | 1 |
| Sonneveld, E | 1 |
| Veerman, AJ | 1 |
| Kamps, WA | 1 |
| Horstmann, M | 1 |
| Petricoin, EF | 1 |
| Pieters, R | 1 |
| Meijerink, JP | 1 |
| Kox, C | 1 |
| Leible, S | 1 |
| Koehler, R | 1 |
| Tolle, G | 1 |
| Breit, S | 1 |
| Muckenthaler, MU | 1 |
| Niino, D | 1 |
| Ohsaki, K | 1 |
| Arakawa, F | 1 |
| Watanabe, J | 1 |
| Kimura, Y | 1 |
| Kiyasu, J | 1 |
| Takeuchi, M | 1 |
| Miyoshi, H | 1 |
| Sugita, Y | 1 |
| Ohshima, K | 1 |
| Okamura, T | 1 |
| Inukai, T | 1 |
| Kiyokawa, N | 1 |
| Campana, D | 1 |
| Coustan-Smith, E | 1 |
| Kikuchi, A | 1 |
| Kobayashi, M | 1 |
| Koh, K | 1 |
| Kumagai, M | 1 |
| Ikuta, K | 1 |
| Hayashi, Y | 1 |
| Tsuchida, M | 1 |
| Sugita, K | 1 |
| Ohara, A | 1 |
| Lauten, M | 1 |
| Meissner, B | 1 |
| Odenwald, E | 1 |
| Niemeyer, C | 1 |
| Riehm, H | 1 |
| Le Guellec, C | 1 |
| Benz-de Bretagne, I | 1 |
| Jonville-Bera, AP | 1 |
| Tarfaoui, N | 1 |
| Andres, CR | 1 |
| Gendrot, C | 1 |
| Jourdain, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma[NCT00408005] | Phase 3 | 1,895 participants (Actual) | Interventional | 2007-01-22 | Active, not recruiting | ||
| Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)[NCT00275106] | Phase 3 | 600 participants (Anticipated) | Interventional | 2004-09-30 | Terminated (stopped due to Withdrawn due to an excess of toxic deaths) | ||
| ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia[NCT00430118] | Phase 3 | 4,559 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia[NCT00613457] | Phase 3 | 2,039 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction
| Intervention | percent probability (Number) |
|---|---|
| ARM I and ARM II (Combination Chemotherapy) | 91.45 |
| ARM III and ARM IV (Combination Chemotherapy) | 85.78 |
Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction
| Intervention | percent probability (Number) |
|---|---|
| ARM I (Combination Chemotherapy) | 91.76 |
| ARM II (Combination Chemotherapy) | 90.53 |
| ARM III (Combination Chemotherapy) | 86.06 |
| ARM IV (Combination Chemotherapy) | 84.89 |
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event (NCT00408005)
Timeframe: 4 years from randomization at the end of induction
| Intervention | percent probability (Number) |
|---|---|
| ARM I and ARM III (Combination Chemotherapy) | 82.96 |
| ARM II and ARM IV (Combination Chemotherapy) | 88.30 |
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction
| Intervention | percent probability (Number) |
|---|---|
| ARM I (Combination Chemotherapy) | 89.01 |
| ARM II (Combination Chemotherapy) | 90.53 |
| ARM III (Combination Chemotherapy) | 78.07 |
| ARM IV (Combination Chemotherapy) | 86.46 |
Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction
| Intervention | percent probability (Number) | |
|---|---|---|
| Intermediate Risk | High Risk | |
| ARM II (Combination Chemotherapy) | 1.08 | 0 |
| ARM IV (Combination Chemotherapy) | 0.85 | 3.45 |
Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction
| Intervention | percent probability (Number) | ||
|---|---|---|---|
| Low Risk | Intermediate Risk | High Risk | |
| ARM I (Combination Chemotherapy) | 1.85 | 1.16 | 3.64 |
| ARM III (Combination Chemotherapy) | 1.92 | 9.1 | 6.52 |
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction
| Intervention | percent probability (Number) | |
|---|---|---|
| High Risk | Induction Failure | |
| ARM II (Combination Chemotherapy) | 85.0 | 100 |
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction
| Intervention | percent probability (Number) | |
|---|---|---|
| Standard Risk | High Risk | |
| ARM I (Combination Chemotherapy) | 87.4 | 85.1 |
2 reviews available for prednisone and Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Topics: Extracellular Signal-Regulated MAP Kinases; Glucocorticoids; Humans; Precursor Cell Lymphoblastic Le | 2022 |
[Posterior reversible encephalopathy syndrome following paralytic ileus caused by vincristine in a patient with T cell lymphoblastic lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Induc | 2014 |
9 trials available for prednisone and Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Asparaginase; Child; | 2020 |
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Epigenesis, Genetic; | 2021 |
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Europe; Female; Humans; Infant; Male; Precursor | 2017 |
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD13 Antigens; CD56 An | 2018 |
PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2019 |
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child | 2013 |
Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2015 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, | 2012 |
27 other studies available for prednisone and Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Topics: Biomarkers; Humans; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic L | 2023 |
[Expression of
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Relevance; Disease-Free Survival; Hu | 2023 |
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2020 |
Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Penile Diseases | 2020 |
Clinical features and outcome of pediatric acute lymphoblastic leukemia with low peripheral blood blast cell count at diagnosis.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Female; Humans; Infant; Infant | 2021 |
COVID-19 reinfection in two children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carboplatin; Child, Presch | 2021 |
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Topics: Adolescent; Adult; Aged; Allografts; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemo | 2021 |
Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2018 |
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2018 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combin | 2013 |
Augmenting clinical interpretability of thiopurine methyltransferase laboratory evaluation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromatography, High Press | 2014 |
Case report: An unusual presentation of oral acute graft-versus-host-disease in a haploidentical hematopoietic stem cell transplant recipient.
Topics: Adolescent; Glucocorticoids; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2016 |
[Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
Topics: Bone Marrow; Child; China; Disease-Free Survival; Flow Cytometry; Humans; Leukocyte Count; Lost to F | 2016 |
Paraneoplastic Galactorrhea in Childhood T-ALL: An Evaluation of Tumor-derived Prolactin.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Asparaginase; Chromosome Del | 2017 |
[Cutaneous involvement in T-lymphoblastic lymphoma].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Cyclophos | 2017 |
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; | 2009 |
Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality | 2009 |
Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aus | 2010 |
[Transient hyperlipidemia secondary to treatment with asparaginase and prednisone].
Topics: Antineoplastic Agents; Asparaginase; Child; Glucocorticoids; Humans; Hyperlipidemias; Male; Precurso | 2010 |
Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Anti | 2010 |
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Hormonal; Antipsychotic Agents; Child; Dexa | 2010 |
Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Chromosomes, Human, Pair 13; Chromosomes, Hum | 2010 |
NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
Topics: Cell Cycle Proteins; Child; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Gene Rearr | 2010 |
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.
Topics: Cell Cycle Proteins; Child; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Humans; Mutation; | 2010 |
Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Pro | 2011 |
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15.
Topics: Adolescent; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Child; | 2012 |
A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; ATP Binding Cassette T | 2012 |